Aurinia Pharmaceuticals (AUPH) Accumulated Depreciation & Amortization (2019 - 2025)
Aurinia Pharmaceuticals (AUPH) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $14.6 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accumulated Depreciation & Amortization changed 0.01% year-over-year to $14.6 million, compared with a TTM value of $14.6 million through Sep 2025, changed 0.01%, and an annual FY2024 reading of $19.4 million, up 66.95% over the prior year.
- Accumulated Depreciation & Amortization was $14.6 million for Q3 2025 at Aurinia Pharmaceuticals, up from $9.7 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $19.4 million in Q4 2024 and bottomed at $506000.0 in Q2 2021.
- Average Accumulated Depreciation & Amortization over 5 years is $6.7 million, with a median of $4.8 million recorded in 2024.
- The sharpest move saw Accumulated Depreciation & Amortization decreased 1.99% in 2022, then skyrocketed 731.41% in 2024.
- Year by year, Accumulated Depreciation & Amortization stood at $2.8 million in 2021, then decreased by 1.99% to $2.7 million in 2022, then surged by 330.41% to $11.6 million in 2023, then surged by 66.95% to $19.4 million in 2024, then dropped by 24.99% to $14.6 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for AUPH at $14.6 million in Q3 2025, $9.7 million in Q2 2025, and $4.9 million in Q1 2025.